1. Home
  2. TLAC vs IPHA Comparison

TLAC vs IPHA Comparison

Compare TLAC & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TLAC

Three Lions Acquisition Corp. Ordinary Shares

N/A

Current Price

$9.83

Market Cap

141.9M

Sector

N/A

ML Signal

N/A

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.35

Market Cap

167.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TLAC
IPHA
Founded
2026
1999
Country
United States
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
141.9M
167.6M
IPO Year
2026
2014

Fundamental Metrics

Financial Performance
Metric
TLAC
IPHA
Price
$9.83
$1.35
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $6.67
AVG Volume (30 Days)
6.2K
★ 24.7K
Earning Date
N/A
09-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$390.56
Revenue Next Year
N/A
$143.06
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.83
$1.17
52 Week High
$9.89
$2.71

Technical Indicators

Market Signals
Indicator
TLAC
IPHA
Relative Strength Index (RSI) 40.55 33.79
Support Level N/A $1.17
Resistance Level $9.87 $1.59
Average True Range (ATR) 0.01 0.07
MACD -0.00 0.00
Stochastic Oscillator 0.00 3.85

Price Performance

Historical Comparison
TLAC
IPHA

About TLAC Three Lions Acquisition Corp. Ordinary Shares

Three Lions Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: